
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is expected to see continued growth in their respiratory-focused commercial portfolio and clinical pipeline, as well as potential success in their innovative research programs. While there are risks involved, strong second quarter results and adjusted revenue estimates show a promising outlook. INSM's focus on sustainability and responsible practices also aligns with current market trends and could positively impact future performance.
Bears say
Insmed is a biopharmaceutical company with two commercial products in the respiratory therapeutic area. While the recent strong sales and increased guidance for these products is encouraging, the success of the company ultimately depends on the continued execution of these launches and the potential success of their clinical stage programs in other therapeutic areas. However, risks include lack of de-risking data for additional indications and potential challenges in successfully commercializing the products in a competitive market. Therefore, a long-term positive outlook on Insmed's stock is dependent on a combination of factors, including steady revenue growth, pipeline success, and potential acquisition by a larger company.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares